Morgan Stanley Achilles Therapeutics PLC Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 8,931 shares of ACHL stock, worth $9,020. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,931

Previous 18,201 50.93%

Holding current value

$9,020

Previous $22,000 68.18%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.75 - $1.25 $6,952 - $11,587	-9,270 Reduced 50.93%	8,931 $7,000
Q1 2024 Aug 16, 2024	BUY	$0.82 - $1.57 $14,908 - $28,544	18,181 Added 90905.0%	18,201 $22,000
Q1 2024 May 15, 2024	BUY	$0.82 - $1.57 $14,908 - $28,544	18,181 Added 90905.0%	18,201 $22,000
Q4 2023 Aug 16, 2024	SELL	$0.78 - $0.96 $6,950 - $8,554	-8,911 Reduced 99.78%	20 $0
Q4 2023 Feb 13, 2024	SELL	$0.78 - $0.96 $39,000 - $48,000	-50,000 Reduced 99.96%	20 $0
Q3 2023 Nov 15, 2023	SELL	$0.84 - $1.11 $19,095 - $25,233	-22,733 Reduced 31.25%	50,020 $45,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.09 $172,942 - $229,887	-210,906 Reduced 74.35%	72,753 $69,000
Q1 2023 May 15, 2023	BUY	$0.84 - $1.26 $238,273 - $357,410	283,659 New	283,659 $272,000
Q3 2022 Nov 14, 2022	BUY	$2.26 - $3.38 $1,850 - $2,768	819 Added 12.93%	7,155 $16,000
Q2 2022 Oct 27, 2022	BUY	$1.96 - $3.04 $225 - $349	115 Added 1.85%	6,336 $16,000
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.04 $225 - $349	115 Added 1.85%	6,336 $16,000
Q1 2022 Oct 27, 2022	SELL	$2.8 - $5.23 $322 - $601	-115 Reduced 1.82%	6,221 $18,000
Q1 2022 May 13, 2022	SELL	$2.8 - $5.23 $358 - $669	-128 Reduced 2.02%	6,221 $18,000
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $26,792 - $56,252	6,349 New	6,349 $32,000

Others Institutions Holding ACHL

# of Institutions

Shares Held

22.2M

Call Options Held

Put Options Held

View Full List

About Achilles Therapeutics plc

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $41.2M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

More about ACHL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account